BioMedPartners was one of the first venture capital firms in continental Europe to focus only on life sciences, building its funds and team around Switzerland and Germany with deep ties to Roche, ETH, and the University of Basel, and its partners have personally founded and sold companies like GlycoVaxyn (to GSK) and Inositec (to Vifor Pharma). The firm has repeatedly backed specific, less obvious scientific bets—such as Claudin-1 as an anti-fibrotic target at Alentis, cancer drug resistance biology at Tolremo, and early T-cell vaccine platforms at Okairos—and its portfolio includes major exits like Tubulis (up to $5 billion Gilead deal), Cardior (Novo Nordisk), Numab/Yellow Jersey (J&J), and NBE-Therapeutics (Boehringer Ingelheim).